Shrnutí - 10 let existence

THE CZECH MYELOMA GROUP - INTRODUCTION AND HISTORICAL OVERVIEW

The Czech Myeloma Group (CMG) was established in 1996. The main objective of the CMG is to organize and coordinate research and clinical activities in the Czech Republic in the area of multiple myeloma. It ensures that the best current standards of care for patients with multiple myeloma are met. Its clinical studies provide the Czech patients with multiple myeloma the access to the latest experimental treatments in the field.

As the activities spread out, The Czech Myeloma Group Foundation was established in 2001 to give support to patient related activities and promotions.

All activities of The CMG and of its Foundation are directed at improvements of the treatment of multiple myeloma in the Czech Republic. Also, both organizations aim to provide a relief from the many problems and conditions that limit the quality of life of patients suffering from multiple myeloma.

 

A brief history of The CMG

1996

CMG founded

2001

CMG Foundation established

2003

Cooperation with The International Myeloma Foundation (IMF) initiated

2005

Communication among countries of Central and Eastern Europe within the new multicenter clinical trial started

2006

Independent Patient organization established

2006

Monoclonal Gammopathy and Multiple Myeloma Basic Research Centre founded

2007

CMG became a partner of The IMF

 

FUNDAMENTAL PHILOSOPHY OF THE CMG AND THE CMG FOUNDATION

The CMG is an association of physicians and other researchers with main interest in scientific investigation, diagnostics and therapy of multiple myeloma and monoclonal gammopathy.

Goals:

 

The CMG Foundation is an association of healthcare givers formed to meet the special needs of patients suffering from multiple myeloma, their families and friends.

Goals:

 

THE CMG AND THE CMG FOUNDATION ACTIVITIES

Concentration on physicians and professional community

 

 

A brief activities focused on physicians

1996

The first multicentric study 4W started

2002

The second multicentric trial CMG 2002 initiated

2003

Guidelines for treatment of Multiple myeloma published

2005

Guidelines for treatment of Multiple myeloma upgraded

2007

Registry of monoclonal gammopathies opened

2007

Educational program CRAB (Toward a better quality of life through an earlier diagnosis) launched

 

Concentration on the patients

 

 

A brief activities focused on the patients 

2002

Model project of waiting room in out-patient clinic finished

2002

HOT-LINE installed

2002

The benefit performances held regularly

2003

Patients brochures published regularly in association with The IMF

2005

The first Patient & Family Seminar held  in Lednice

2006

Independent Patient organization established

2006

The second Patient & Family Seminar held  in Podebrady

2007

The third Patient & Family Seminar held  in Lednice

 

 

Treatments accessibility

1996

Autologous transplantation implemented to the treatment regimen

2002

More than 80% of patients indicated for autologous transplantation benefit from this treatment

2001

Thalidomide introduced in the Czech Republic

2004

Thalidomide reimbursed for relapsed patients

2004

Bortezomib introduced in the Czech Republic through Velcade  initiation  programME

2005

Bortezomib reimbursed for relapsed patients

2007

Thalidomide reimbursed for newly diagnosed patients

2007

Lenalidomide introduced in the Czech Republic through LENALIDOMIDE NAMED  PATIENT PROGRAMME

Concentration on research

The preclinical research was focused mainly on immunotherapy, development of anti-tumor vaccines respectively in the period 1998-2002. More complex research program, established in the year 2002, finally led to opening new Monoclonal Gammopathy and Multiple Myeloma Basic Research Centre in Brno as the reference research centre of The Czech Myeloma Group. This centre works closely with academic field and participates in clinical activities of the Czech Myeloma Group which gives a great opportunity to promote research on multiple myeloma and monoclonal gammopathy. The centre connection with academic field and coordination with clinical activities of The Czech Myeloma Group gives a great opportunity to reinforce research of multiple myeloma and monoclonal gammopathy. The main research projects are focused on pharmocogenomics and proteomics.  

A brief preclinical research

1998

Laboratory of hematology and experimental immunotherapy founded

2003

The first anti-myeloma vaccine applied

2004

Biological sample bank and databases opened

2005

Project Bank on a Cure - participation in the Czech Republic initiated

2006

Monoclonal Gammopathy and Multiple Myeloma Basic Research Centre founded

The clinical research is mainly directed at the autologous transplantation and the role of maintenance and/or consolidation therapy. It is also focused on the re-transplantation for relapsed patients and on the phase I / II studies using anti-tumor vaccines.

A brief clinical research - trials

Clinical trials conducted by the CMG

1996-2002

4W - maintenance th. after autologous transplantation in newly diagnosed pts.

2002-2007

CMG 2002 - maintenance or consolidation th. after autologous transplantation in newly diagnosed pts.

1998

T2 model - re-transplantation and experimental th. after transplantation

2003

Anti-myeloma vaccine (KLH-Id protein)

2005

Prognostic impact of genetic abnormalities in the area of new drugs

2006

Anti-myeloma vaccine (dendritic cells)

 

PRESENT PROJECTS AND PLANS FOR THE FUTURE

Education programs (EP): 

CRAB - Toward a better quality of life through an earlier diagnosis
Program is focused on family physicians and key out-patients physicians responsible for recognizing the symptoms related to MM (specialists of rheumatology, neurology, orthopedic or nephrology).
Initiation: 2007
Duration: 2007-2011
Anticipated outcome:

 

Transfer of methods
Program is focused on the standardization of laboratory examination methods in multiple myeloma in Central and Eastern Europe (incl. Czech Republic, Slovakia, Poland and Hungary).
Guaranteed by Monoclonal Gammopathy and Multiple Myeloma Basic Research Centre
Initiation: 2006
Outcome:

International workshops:

 

Register of Monoclonal Gammopathies (RMG register)

Project MGUS 2007 - "2000 data sets in 2 year"
Initiation: 2007
Data-info part: follow up steps

Targets:

Research part: utilization of substantive information from RMG register and evaluation of samples stored in MM bank from pts. with MGUS and MM.
Aims: 

  1. Evaluation of pharmacogenomic  and  pharmacoproteomics for the determination of resistance and sensitivity to anti-myeloma drugs
  2. Identification and validation of clinically applicable model for the selection of optimal anti-myeloma treatment on the basis of genomic and proteomic markers
  3. Identification of proteome differences between benign and mclassant gammopathies 
  4. Creation of new model superior to currently used systems for the identification of high-risk MGUS patients